| abstract |
The present invention relates to compounds of the formula I in which the main substituents are R-NH-C (X) -NH- (CR 13 R 14) v -Z; ZW, optionally substituted heteroaryl, cycloalkyl, alkyl, alkenyl or alkynyl; X is oxo or thioxo; A is -CR20R21; R1 is hydrogen, halogen, nitro, cyano, haloalkyl, alkyl, alkenyl, alkoxy, haloalkoxy, azido, - (CR8R8) qS (O) tR4, hydroxy, hydroxyalkyl -, aryl, arylalkyl, aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, heteroarylalkoxy, arylalkenyl, heteroarylalkenyl- , heterocyclylalkenyl, - (CR 8 R 8) q NR 4 R 5, -alkenyl-C (O) NR 4 R 5, - (CR 8 R 8) q C (O) NR 4 R 5, - (CR 8 R 8) q C (O) NR 4 R 10, -S (O) 3 R 8, - ( CR 8 R 8) q C (O) R 11, -alkenyl-C (O) R 11, -alkenyl-C (O) OR 11. -C (O) R11, - (CR8R8) qC (O) OR12, - (CR8R8) qOC (O) R11 - (CR8R8) qNR4C (O) R11, - (CR8R8) qC (NR4) NR4R5, - (CR8R8) qNR4C (NR5) R11, - (CR8R8) qNHS (O) 2R17 or - (CR8R8) qS (O) 2NR4R5; or two R 1 groups may be taken together to form -O- (CH 2) S-O- or a cyclic group; n, m and s are 1, 2 or 3; q is 0, 1, 2, 3, 4, 5, 6,7, 8, 9 or 10; t value. 0, 1 or v is 0, 1, 2, 3 or 4; This optionally refers to a group wherein the asterisks (*) represent ring attachment points - and are pharmaceutical compositions for treating a disease comprising compounds that are mediated by IL-8 or IL-8 receptor binding chemokine. HE |